{
    "clinical_study": {
        "@rank": "41918", 
        "acronym": "HYPOTESIS", 
        "arm_group": [
            {
                "arm_group_label": "acipimox+", 
                "arm_group_type": "Experimental", 
                "description": "250 mg at 0 and 180 minutes (one day)"
            }, 
            {
                "arm_group_label": "acipimox-", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1 Tablet at 0 and 180 minutes (one day)"
            }
        ], 
        "brief_summary": {
            "textblock": "There is evidence that inhibition of FFA-release by acipimox is associated with a\n      significant decrease in myocardial lipid content (MYCL) as well as the ejection fraction (as\n      a marker of systolic left ventricular function) in healthy subjects, indicating, that the\n      heart is dependent on a constant supply of free fatty acids in order to guarantee normal\n      cardiac function, and it further indicates, that the heart is not able to cover its energy\n      demand by switching to glucose oxidation.\n\n      Since that phenomenon, better known as \"metabolic inflexibility\" has been mainly described\n      in patients with diabetes, we aim to investigate the impact of FFA-inhibition on MYCL and\n      cardiac function in patients with overt type 2 diabetes."
        }, 
        "brief_title": "The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes", 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 2 Diabetes\n\n          -  HbA1C >6%\n\n        Exclusion Criteria:\n\n          -  Insulin therapy (except: BOT=basal supported oral therapy)\n\n          -  Known heart disease including coronary artery disease, cardiomyopathy, history of\n             cardiac surgery\n\n          -  Known intolerance against niacins\n\n          -  Known contra-indications against magnetic resonance (MR-) examinations"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01980524", 
            "org_study_id": "HYPOTESIS", 
            "secondary_id": "2013-002656-32"
        }, 
        "intervention": {
            "arm_group_label": [
                "acipimox+", 
                "acipimox-"
            ], 
            "intervention_name": "acipimox", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Acipimox"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 4, 2013", 
        "location": {
            "contact": {
                "email": "peter.wolf@meduniwien.ac.at", 
                "last_name": "Peter Wolf, MD", 
                "phone": "+43 1 40400 2069"
            }, 
            "facility": {
                "address": {
                    "city": "Vienna", 
                    "country": "Austria", 
                    "zip": "1090"
                }, 
                "name": "Division of Endocrinology and Metabolism, Internal Medicine III, Medical University of Vienna"
            }, 
            "investigator": [
                {
                    "last_name": "Michael Krebs, Prof.MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Yvonne Winhofer, MD PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "official_title": "HYPOglycemia Linked to Cardiac sTEatoSIS? - Identifying Mechanisms That Explain Adverse Cardiovascular Outcome Associated With Intensive Glucose Control in Patients With Diabetes (HYPOTESIS)", 
        "other_outcome": {
            "measure": "stroke volume", 
            "safety_issue": "No", 
            "time_frame": "2 hours"
        }, 
        "overall_contact": {
            "email": "yvonne.winhofer@meduniwien.ac.at", 
            "last_name": "Yvonne Winhofer, MD PhD", 
            "phone": "+43 1 40400 4311"
        }, 
        "overall_contact_backup": {
            "email": "peter.wolf@meduniwien.ac.at", 
            "last_name": "Peter Wolf, MD", 
            "phone": "+43 1 40400 2069"
        }, 
        "overall_official": {
            "affiliation": "Medical University of Vienna, Dept. of Internal Medicine III, Division of Endocrinology and Metabolism", 
            "last_name": "Michael Krebs, Prof.MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "MYCL", 
            "safety_issue": "No", 
            "time_frame": "2 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980524"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of Vienna", 
            "investigator_full_name": "Prof. Dr. Michael Krebs", 
            "investigator_title": "Prof.MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Ejection fraction", 
            "safety_issue": "No", 
            "time_frame": "2 hours"
        }, 
        "source": "Medical University of Vienna", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of Vienna", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}